company background image

Phio Pharmaceuticals NasdaqCM:PHIO Stock Report

Last Price


Market Cap







05 Dec, 2022


Company Financials +
PHIO fundamental analysis
Snowflake Score
Future Growth5/6
Past Performance0/6
Financial Health6/6

PHIO Stock Overview

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.

Phio Pharmaceuticals Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Phio Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.41
52 Week HighUS$2.42
52 Week LowUS$0.39
1 Month Change-27.81%
3 Month Change-40.75%
1 Year Change-67.34%
3 Year Change-95.25%
5 Year Change-99.89%
Change since IPO-100.00%

Recent News & Updates

Phio Pharmaceuticals appoints interim executive chairman

Sep 29

Recent updates

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Shareholder Returns

PHIOUS BiotechsUS Market

Return vs Industry: PHIO underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: PHIO underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is PHIO's price volatile compared to industry and market?
PHIO volatility
PHIO Average Weekly Movement8.7%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: PHIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PHIO's weekly volatility has decreased from 25% to 9% over the past year.

About the Company

201112Geert Cauwenbergh

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT.

Phio Pharmaceuticals Corp. Fundamentals Summary

How do Phio Pharmaceuticals's earnings and revenue compare to its market cap?
PHIO fundamental statistics
Market CapUS$5.54m
Earnings (TTM)-US$12.20m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHIO income statement (TTM)
Cost of RevenueUS$7.62m
Gross Profit-US$7.62m
Other ExpensesUS$4.58m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.89
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PHIO perform over the long term?

See historical performance and comparison